¼¼°èÀÇ ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀå
Viral Vector Manufacturing
»óǰÄÚµå : 1761125
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 402 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,106,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,320,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 26¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9¾ï 5,360¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 18.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 26¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ·¹Æ®·Î¹ÙÀÌ·¯½º º¤ÅÍ´Â CAGR 18.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9¾ï 5,460¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Æµ¥³ë¹ÙÀÌ·¯½º º¤ÅÍ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 18.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5¾ï 6,900¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 21.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀåÀº 2024³â¿¡ 5¾ï 6,900¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 790¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 21.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, °¢°¢ ºÐ¼® ±â°£ µ¿¾È¿¡ 15.6%¿Í 15.1%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 14.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶´Â À¯ÀüÀÚ Ä¡·á, ¹é½Å °³¹ß, ¾Ï Ä¡·á ºÐ¾ß¿¡¼­ Áß¿äÇÑ °úÁ¤À¸·Î, ¼¼Æ÷ ³»·Î À¯Àü ¹°ÁúÀ» Àü´ÞÇϵµ·Ï ¼³°èµÈ ¹ÙÀÌ·¯½ºÀÇ »ý»êÀ» ¼ö¹ÝÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º¤ÅÍ´Â ¾Æµ¥³ë¹ÙÀÌ·¯½º, ·»Æ¼¹ÙÀÌ·¯½º, ¾Æµ¥³ë ºÎ¼Ó ¹ÙÀÌ·¯½º(AAV)¿¡¼­ À¯·¡ÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, À¯ÀüÀÚ °á¼ÕÀ» ±³Á¤Çϰųª, ¸é¿ª¹ÝÀÀÀ» À¯µµÇϰųª, ¾Ï¼¼Æ÷¸¦ ÆÄ±«ÇÏ´Â Ä¡·á À¯ÀüÀÚ¸¦ µµÀÔÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ¹ÙÀÌ·¯½º º¤ÅÍÀÇ Á¦Á¶´Â º¹ÀâÇÏ°í °íµµ·Î ±ÔÁ¦µÈ °øÁ¤À¸·Î Ư¼öÇÑ Àåºñ, ¾ö°ÝÇÑ Ç°Áú °ü¸®, ÀûÁ¤ Á¦Á¶ ±Ô¹ü(GMP)ÀÇ Áؼö¸¦ ÇÊ¿ä·Î ÇÕ´Ï´Ù. Á¦Á¶ °øÁ¤¿¡´Â º¤ÅÍ ¼³°è, ¾÷½ºÆ®¸² Á¦Á¶(¼¼Æ÷¹è¾ç ¹× ¹ÙÀÌ·¯½º ÁõÆø), ´Ù¿î½ºÆ®¸² ó¸®(Á¤Á¦ ¹× ³óÃà), ±×¸®°í ¹ÙÀÌ·¯½º º¤ÅÍÀÇ ¾ÈÀü¼º, ¿ª°¡, ¼øµµ¸¦ º¸ÀåÇϱâ À§ÇÑ ÃÖÁ¾ Á¦Á¦È­ ¹× ǰÁú Å×½ºÆ® µî ¿©·¯ ´Ü°è°¡ Æ÷ÇԵ˴ϴÙ.

¹ÙÀÌ·¯½º º¤ÅÍ »ý»êÀÇ µ¿ÇâÀº ±â¼ú ¹× »ý»ê´É·Â¿¡ ÀÖ¾î °ý¸ñÇÒ ¸¸ÇÑ ÁøÀüÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸®¾×ÅÍ ¼³°è¿Í ¼¼Æ÷¹è¾ç ±â¼úÀÇ Çõ½ÅÀ¸·Î ¹ÙÀÌ·¯½º º¤ÅÍ »ý»êÀÇ È®À强°ú È¿À²¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ¿Í ¿¬¼Ó »ý»ê °øÁ¤Àº »ý»êÀ» °£¼ÒÈ­ÇÏ°í ¿À¿° À§ÇèÀ» ÁÙÀ̱â À§ÇØ Á¡Á¡ ´õ ¸¹ÀÌ Ã¤Åõǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Å©·Î¸¶Åä±×·¡ÇÇ ¹× ¿©°ú¿Í °°Àº Á¤Á¦ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¹ÙÀÌ·¯½º º¤ÅÍÀÇ ¼öÀ²°ú ǰÁúÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­¿Í ½Ç½Ã°£ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ ÅëÇÕÀ¸·Î Á¦Á¶ °øÁ¤ÀÌ ´õ¿í ÃÖÀûÈ­µÇ¾î º¸´Ù ÀϰüµÇ°í ÀçÇö¼º ÀÖ´Â º¤ÅÍ »ý»êÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó ¹× »ó¾÷¿ë ¹ÙÀÌ·¯½º º¤ÅÍ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ºñ¿ë È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀÇ °³¹ßÀÌ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. Çаè, »ý¸í°øÇÐ ±â¾÷, À§Å¹»ý»ê¾÷ü(CMO)ÀÇ Çù¾÷Àº ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí Àü ¼¼°è ¹ÙÀÌ·¯½º º¤ÅÍ »ý»ê´É·ÂÀ» È®ÀåÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÀÓ»ó °³¹ß ÁßÀÎ À¯ÀüÀÚ Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÇ È®´ë´Â ¹ÙÀÌ·¯½º º¤ÅÍ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô Áõ°¡½Ã۰í ÀÖÀ¸¸ç, Luxturna¿Í Zolgensma¿Í °°Àº À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ ¼º°ø°ú CAR-T ¼¼Æ÷ Ä¡·áÁ¦ÀÇ ½ÂÀÎÀº ³­Ä¡¼º ÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ·¯½º º¤ÅÍÀÇ ÀáÀç·ÂÀ» ÀÔÁõÇß½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀº ¶ÇÇÑ ¹é½Å °³¹ß¿¡¼­ ¹ÙÀÌ·¯½º º¤ÅÍÀÇ Á߿伺À» ºÎ°¢½ÃÄ×À¸¸ç, Á¸½¼¾ØµåÁ¸½¼°ú ¾Æ½ºÆ®¶óÁ¦³×Ä«°¡ °³¹ßÇÑ ¹é½ÅÀ» Æ÷ÇÔÇÑ ¿©·¯ ¹é½ÅÀÌ ¹ÙÀÌ·¯½º º¤ÅÍ ±â¼úÀ» Ȱ¿ëÇÑ ¹é½ÅÀ¸·Î °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¹é½ÅÀÌ ¹ÙÀÌ·¯½º º¤ÅÍ ±â¼úÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¤ÅÍ °øÇÐ ¹× Á¦Á¶ ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¦Á¶ °øÁ¤ÀÇ È¿À²¼º°ú È®À强ÀÌ Çâ»óµÇ¾î ¹ÙÀÌ·¯½º º¤ÅÍ ¿ä¹ýÀ» º¸´Ù ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°í ºñ¿ë È¿À²¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. Á¤ºÎ ±â°ü°ú ¹Î°£ ÅõÀÚÀÚµéÀÇ ±ÔÁ¦ Áö¿ø°ú ÀÚ±Ý Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷, Çаè, CMO °£ÀÇ Çù·Â°ú Á¦ÈÞ°¡ Áõ°¡Çϸ鼭 »ý»ê´É·ÂÀ» È®´ëÇÏ°í ¹ÙÀÌ·¯½º º¤ÅÍ ±â¹Ý Ä¡·áÁ¦ÀÇ °³¹ß ¹× »ó¿ëÈ­¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕÇÏ¿© ¹ÙÀÌ·¯½º º¤ÅÍ Á¦Á¶ ½ÃÀåÀÇ °ßÁ¶ÇÑ ¼ºÀåÀ» º¸ÀåÇϰí Áö¼ÓÀûÀÎ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ¸ç ´Ù¾çÇÑ Ä¡·á ÀÀ¿ë ºÐ¾ß¿¡ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(·¹Æ®·Î¹ÙÀÌ·¯½º º¤ÅÍ, ¾Æµ¥³ë¹ÙÀÌ·¯½º º¤ÅÍ, ¾Æµ¥³ë ºÎ¼Ó ¹ÙÀÌ·¯½º º¤ÅÍ, ±âŸ À¯Çü), Áúȯ(¾Ï, À¯ÀüÁúȯ, °¨¿°Áõ, ±âŸ Áúȯ), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾à¡¤¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷, Á¶»ç±â°ü)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 80°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è µµ¸ÞÀÎ Àü¹®°¡°¡ ¼±º°ÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Viral Vector Manufacturing Market to Reach US$2.6 Billion by 2030

The global market for Viral Vector Manufacturing estimated at US$953.6 Million in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 18.3% over the analysis period 2024-2030. Retroviral Vectors, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$954.6 Million by the end of the analysis period. Growth in the Adenoviral Vectors segment is estimated at 18.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$569.0 Million While China is Forecast to Grow at 21.3% CAGR

The Viral Vector Manufacturing market in the U.S. is estimated at US$569.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$107.9 Million by the year 2030 trailing a CAGR of 21.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Global Viral Vector Manufacturing Market - Key Trends & Drivers Summarized

Viral vector manufacturing is a critical process in the field of gene therapy, vaccine development, and cancer treatment, involving the production of viruses engineered to deliver genetic material into cells. These vectors often derived from adenoviruses, lentiviruses, or adeno-associated viruses (AAVs), are used to introduce therapeutic genes to correct genetic defects, provoke immune responses, or destroy cancer cells. The production of viral vectors is a complex and highly regulated process that requires specialized facilities, stringent quality control, and adherence to good manufacturing practices (GMP). The manufacturing process involves several stages, including vector design, upstream production (cell culture and virus amplification), downstream processing (purification and concentration), and final formulation and quality testing to ensure safety, potency, and purity of the viral vectors.

Trends in viral vector manufacturing highlight significant advancements in technology and production capabilities. Innovations in bioreactor design and cell culture techniques have enhanced the scalability and efficiency of viral vector production. Single-use bioreactors and continuous manufacturing processes are increasingly adopted to streamline production and reduce contamination risks. Additionally, advances in purification technologies, such as chromatography and filtration, have improved the yield and quality of viral vectors. The integration of automation and real-time monitoring systems has further optimized the manufacturing process, allowing for more consistent and reproducible vector production. There is also a growing emphasis on developing cost-effective and scalable solutions to meet the rising demand for viral vectors in clinical and commercial applications. Collaborations between academic institutions, biotech companies, and contract manufacturing organizations (CMOs) are driving innovation and expanding the global capacity for viral vector production.

The growth in the viral vector manufacturing market is driven by several factors. The increasing prevalence of genetic disorders and the expanding pipeline of gene therapies in clinical development have significantly boosted the demand for viral vectors. The success of gene therapies, such as Luxturna and Zolgensma, and the approval of CAR-T cell therapies have demonstrated the potential of viral vectors in treating previously intractable diseases, encouraging further investment and research in this field. The COVID-19 pandemic also underscored the importance of viral vectors in vaccine development, with several vaccines, including those developed by Johnson & Johnson and AstraZeneca, utilizing viral vector technology. Additionally, advancements in vector engineering and manufacturing technologies have enhanced the efficiency and scalability of production processes, making viral vector therapies more accessible and cost-effective. Regulatory support and funding from government agencies and private investors are further propelling market growth. The increasing collaborations and partnerships between biotech companies, academic institutions, and CMOs are expanding manufacturing capabilities and accelerating the development and commercialization of viral vector-based therapies. These factors collectively ensure the robust growth of the viral vector manufacturing market, fostering continuous innovation and wider adoption in various therapeutic applications.

SCOPE OF STUDY:

The report analyzes the Viral Vector Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, Other Types); Disease (Cancer, Genetic Disorders, Infectious Diseases, Other Diseases); End-Use (Pharma & Biopharma Companies, Research Institutes)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 80 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â